ACORUnknown
Acorda Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Acorda Therapeutics, Inc. (ACOR), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ACOR insiders buying or selling?
Acorda Therapeutics, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since January 2018, Trabud has recorded 61 Form 4 filings for ACOR: 1 buys ($12.6K) and 60 sells ($87.1M).
Source: SEC EDGAR Form 4
Key Statistics (January 2018 – Mar 20, 2023)
Total Form 4 filings
61
SEC EDGAR
Insider filers
10
Insider buys (1)
$12.6K
Insider sells (60)
$87.1M
Insider sentiment
Net sellingNet insider flow of $87.1M in net selling since January 2018.
Recent ACOR insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 20, 2023 | Ron Cohen | President and CEO | Purchase | 20.2K | $0.62 | $12.6K | SEC ↗ |
| Mar 21, 2022 | Ron Cohen | President and CEO | Sale | 2.3K | $1.70 | $3.9K | SEC ↗ |
| Dec 4, 2019 | Jane Wasman | President, Intl and GC | Sale | 2.2K | $1.60 | $3.6K | SEC ↗ |
| Dec 4, 2019 | Lauren M Sabella | Chief Commercial Officer | Sale | 1.5K | $1.60 | $2.4K | SEC ↗ |
| Dec 4, 2019 | David Lawrence | Chief, Bus. Ops & PAO | Sale | 1.2K | $1.60 | $1.9K | SEC ↗ |
| Dec 4, 2019 | Ron Cohen | President and CEO | Sale | 4.7K | $1.60 | $7.5K | SEC ↗ |
| Feb 25, 2019 | Lauren M Sabella | Chief Commercial Officer | Sale | 761 | $13.18 | $10.0K | SEC ↗ |
| Feb 25, 2019 | David Lawrence | Chief, Bus. Ops & PAO | Sale | 761 | $13.18 | $10.0K | SEC ↗ |
| Feb 1, 2019 | SCOPIA CAPITAL MANAGEMENT LP | 10% Owner | Sale | 7.0K | $16.01 | $112.0K | SEC ↗ |
| Jan 28, 2019 | SCOPIA CAPITAL MANAGEMENT LP | 10% Owner | Sale | 11.0K | $16.02 | $176.3K | SEC ↗ |
| Jan 24, 2019 | SCOPIA CAPITAL MANAGEMENT LP | 10% Owner | Sale | 97.8K | $16.01 | $1.6M | SEC ↗ |
| Jan 22, 2019 | SCOPIA CAPITAL MANAGEMENT LP | 10% Owner | Sale | 139.4K | $16.68 | $2.3M | SEC ↗ |
| Jan 17, 2019 | SCOPIA CAPITAL MANAGEMENT LP | 10% Owner | Sale | 93.3K | $16.93 | $1.6M | SEC ↗ |
| Jan 15, 2019 | SCOPIA CAPITAL MANAGEMENT LP | 10% Owner | Sale | 40.4K | $17.40 | $702.8K | SEC ↗ |
| Jan 11, 2019 | SCOPIA CAPITAL MANAGEMENT LP | 10% Owner | Sale | 162.5K | $17.18 | $2.8M | SEC ↗ |
| Jan 9, 2019 | SCOPIA CAPITAL MANAGEMENT LP | 10% Owner | Sale | 134.2K | $16.42 | $2.2M | SEC ↗ |
| Jan 7, 2019 | SCOPIA CAPITAL MANAGEMENT LP | 10% Owner | Sale | 55.2K | $16.24 | $896.4K | SEC ↗ |
| Jan 2, 2019 | SCOPIA CAPITAL MANAGEMENT LP | 10% Owner | Sale | 52.9K | $14.99 | $792.8K | SEC ↗ |
| Dec 28, 2018 | SCOPIA CAPITAL MANAGEMENT LP | 10% Owner | Sale | 100.0K | $14.66 | $1.5M | SEC ↗ |
| Dec 26, 2018 | SCOPIA CAPITAL MANAGEMENT LP | 10% Owner | Sale | 40.5K | $13.23 | $536.1K | SEC ↗ |
| Dec 21, 2018 | Lauren M Sabella | Chief Commercial Officer | Sale | 3.8K | $27.84 | $105.1K | SEC ↗ |
| Dec 21, 2018 | SCOPIA CAPITAL MANAGEMENT LP | 10% Owner | Sale | 45.0K | $14.25 | $641.0K | SEC ↗ |
| Dec 19, 2018 | SCOPIA CAPITAL MANAGEMENT LP | 10% Owner | Sale | 121.9K | $16.78 | $2.0M | SEC ↗ |
| Dec 17, 2018 | SCOPIA CAPITAL MANAGEMENT LP | 10% Owner | Sale | 61.9K | $16.21 | $1.0M | SEC ↗ |
| Dec 13, 2018 | SCOPIA CAPITAL MANAGEMENT LP | 10% Owner | Sale | 300.0K | $16.30 | $4.9M | SEC ↗ |
Showing the 25 most recent of 61 Form 4 filings for Acorda Therapeutics, Inc..
Most active ACOR insiders
- SCOPIA CAPITAL MANAGEMENT LP32 filings
- Lauren M Sabella7 filings
- David Lawrence6 filings
- Ron Cohen4 filings
- Burkhard Blank3 filings
Ask anything about ACOR insider activity
Use Trabud's AI agent to query Acorda Therapeutics, Inc.'s Form 4 history in plain English — "Show me ACOR CEO purchases this year" or compare it against any other ticker.
Open the AI agentACOR insider trading FAQ
Are Acorda Therapeutics, Inc. insiders buying or selling?
Acorda Therapeutics, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since January 2018, Trabud has recorded 61 Form 4 filings for ACOR: 1 buys ($12.6K) and 60 sells ($87.1M). Over the full record that is net selling of $87.1M.
How many insiders trade ACOR stock?
10 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Acorda Therapeutics, Inc.. The most recent filing was accepted on Mar 20, 2023.
Where does Trabud get ACOR insider trading data?
All ACOR insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.